Literature DB >> 11079017

Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis.

K Matsui1, W K Riemenschneider, S L Hilbert, Z X Yu, K Takeda, W D Travis, J Moss, V J Ferrans.   

Abstract

BACKGROUND: Little is known of the morphology of the pneumocytes lining the parenchymal cysts in lymphangioleiomyomatosis (LAM).
OBJECTIVE: To evaluate the structural characteristics of the alveolar epithelial cells in LAM.
METHODS: Immunohistochemical and electron microscopic studies were performed on lung tissue from 22 women with pulmonary LAM.
RESULTS: Epithelial cells that reacted with PE-10 (a mouse monoclonal antibody that recognizes the surfactant apoprotein A in type II pneumocytes) and TTF-1 (an antibody that identifies nuclear transcription factor found in type II pneumocytes) were the predominant cell type lining the surfaces of lesions of LAM and normal areas of lung. Scanning and transmission electron microscopic studies confirmed that these cells were type II pneumocytes as demonstrated by (1) apical microvilli, (2) electron-dense lamellar bodies, and (3) cytoplasmic projections that extended from the basal surfaces into the underlying connective tissue, where they made extensive contact with interstitial connective tissue cells. A few cells had morphologic characteristics of type I pneumocytes, including large flat surfaces lacking microvilli. Cells that appeared intermediate between type I and type II pneumocytes were observed occasionally.
CONCLUSIONS: These observations and the reactivity of these cells with antibody to proliferating cell nuclear antigen demonstrate that extensive hyperplasia of type II pneumocytes is a major characteristic of LAM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079017     DOI: 10.5858/2000-124-1642-HOTIPI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  18 in total

Review 1.  Lymphangioleiomyomatosis.

Authors:  Francis X McCormack
Journal:  MedGenMed       Date:  2006-01-18

Review 2.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

3.  Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.

Authors:  Wendy K Steagall; Mario Stylianou; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  JCI Insight       Date:  2019-03-07

4.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

Review 5.  Lymphangioleiomyomatosis and TSC2-/- cells.

Authors:  Thomas N Darling; Gustavo Pacheco-Rodriguez; Alfredo Gorio; Elena Lesma; Cheryl Walker; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

6.  mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.

Authors:  Jane Yu; Elizabeth Petri Henske
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

7.  Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.

Authors:  Rachel B Issaka; Saji Oommen; Shiv K Gupta; Gang Liu; Jeffrey L Myers; Jay H Ryu; Nicholas E Vlahakis
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

8.  Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

Authors:  Xiaoxiao Gu; Jane J Yu; Didem Ilter; Nickolas Blenis; Elizabeth Petri Henske; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

Review 9.  Lymphatic involvement in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo M Taveira-Dasilva; Thomas N Darling; Joel Moss
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.

Authors:  Gustavo Pacheco-Rodriguez; Fumiyuki Kumaki; Wendy K Steagall; Yi Zhang; Yoshihiko Ikeda; Jing-Ping Lin; Eric M Billings; Joel Moss
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.